42174-01-6

Upstream product

• 186581-53-3 diazomethane 
• 20595-45-3 2,4-dichlorocinnamic acid 
• 874-42-0 2,4-dichlorobenzaldeyhde 
• 96-32-2 bromoacetic acid methyl ester 
• 29898-32-6 2,4-dichloro-1-iodo-benzene 
• 292638-85-8 acrylic acid methyl ester 
• 67-56-1 methanol 
• 5927-18-4 trimethyl phosphonoacetate 
• 1067-74-9 Methyl diethylphosphonoacetate 

Downstream Products

• 1504-59-2 3-(2.4-Dichlor-phenyl)-prop-2-en-1-ol 
• 146882-07-7 3-(2,4-dichlorophenyl)propan-1-ol 
• 93962-66-4 1-(3-Bromo-propyl)-2,4-dichloro-benzene 
• 1026334-46-2 Thioacetic acid S-[3-(2,4-dichloro-phenyl)-propyl] ester 
• 1026639-62-2 4-[3-(2,4-Dichloro-phenyl)-propylsulfanyl]-3-oxo-butyric acid methyl ester 
• 1027496-33-8 3-Cyano-4-[3-(2,4-dichloro-phenyl)-propylsulfanyl]-3-hydroxy-butyric acid methyl ester 
• 1207950-18-2 C₁₅H₁₆Cl₂O₆ 
• 1588522-41-1 C₁₄H₁₃Cl₂NO₄ 
• 6974-65-8 (2,4-dichloro-phenyl)-propynoic acid 
• 1338378-16-7 4-chloro-5-(2,4-dichlorophenyl)-1-phenyl-1H-pyrazol-3-ol 
• 1338378-34-9 5-(2,4-dichlorophenyl)-3-ethoxy-1-phenyl-1H-pyrazole 
• 1338378-33-8 5-(2,4-dichlorophenyl)-1-phenyl-1H-pyrazol-3-ol 
• 1338378-19-0 4-chloro-5-(2,4-dichlorophenyl)-3-ethoxy-1-phenyl-1H-pyrazole 
• 1312928-25-8 7-(2,4-dichlorophenyl)-6,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidin-5(4H)-one 

Relevant academic research and scientific papers

Dehydrozingerone derivative and preparation method and application thereof

The invention provides a dehydrozingerone derivative as shown in the description. R-R are each independently selected from hydrogen or halogen or a nitro group or an alkyl group or a substitutedalkoxy group or an alkoxy group or a hydroxyl group; the substituent in the substituted alkoxy group is selected from one or multiple of halogen, a nitro group and a hydroxyl group; R and R areeach independently selected from hydrogen or halogen or nitrogen-containing heterocycle; R is selected from an alkyl group or an alkoxy group or a substituted alkoxy group; the substituent in thesubstituted alkyl group is selected from one or multiple of halogen, a nitro group and a hydroxyl group; X is selected from a hetero atom or a hydroxylamine group. The dehydrozingerone derivative hasbroad-spectrum activity against plant pathogenic fungi and bacteria, and has certain nematicidal activity, and is a lead compound with the broad biological activity.

Synthesis and antibacterial evaluation of novel 11-O-aralkylcarbamoyl-3-O-descladinosylclarithromycin derivatives

A series of novel 11-O-aralkylcarbamoyl-3-O-descladinosylclarithromycin derivatives were designed, synthesized and evaluated for their in vitro antibacterial activity. The results showed that the majority of the target compounds displayed potent activity against erythromycin-susceptible S. pyogenes, erythromycin-resistant S. pneumoniae A22072 expressing the mef gene and S. pneumoniae AB11 expressing the mef and erm genes. Besides, most of the target compounds exhibited moderate activity against erythromycin-susceptible S. aureus ATCC25923 and B. subtilis ATCC9372. In particular, compounds 11a, 11b, 11c, 11e, 11f and 11h were found to exert favorable antibacterial activity against erythromycin-susceptible S. pyogenes with the MIC values of 0.015–0.125 μg/mL. Furthermore, compounds 10e, 11a, 11b and 11c showed superior activity against erythromycin-resistant S. pneumoniae A22072 with the MIC values of 0.25–0.5 μg/mL. Additionally, compound 11c was the most effective against all the erythromycin-resistant S. pneumoniae strains (A22072, B1 and AB11), exhibiting 8-, 8- and 32-fold more potent activity than clarithromycin, respectively.

Hydrogen Peroxide Promoted Mizoroki-Heck Reactions of Phenyldiazenes with Acrylates, Acrylamides, and Styrenes

Mizoroki-Heck reactions, which are well-known for aryldiazonium salts and which have recently been described for arylhydrazines, have now been extended to phenyldiazenes. In situ generation of phenyldiazenes from azocarboxylates allowed clean and selective reactions with styrenes, acrylates, and acrylamides using palladium(II) acetate in the presence of silver(I) acetate or hydrogen peroxide as oxidant. Hydrogen peroxide was thereby shown to be a cheap and broadly applicable alternative for the established palladium-silver(I) system.

Design, synthesis and biological evaluation of novel aminomethyl- piperidones based DPP-IV inhibitors

A series of novel aminomethyl-piperidones were designed and evaluated as potential DPP-IV inhibitors. Optimized analogue 12v ((4S,5S)-5-(aminomethyl)-1- (2-(benzo[d][1,3]dioxol-5-yl)ethyl)-4-(2,5-difluorophenyl)piperidin-2-one) showed excellent in vitro p

Phosphine-catalyzed domino reactions: A route to functionalized bicyclic skeletons

A novel strategy that involves phosphine-catalyzed sequential [2+3] and [3+2] annulation reactions was developed. In this domino reaction, γ-substituted allenoates were used as novel C4 synthons, and the bicyclic cyclopenta[b]dihydrofuran derivatives were produced in good to excellent diastereoselectivities and yields under mild conditions. Furthermore, preliminary studies on an asymmetric variant of this reaction proceeded with moderate enantioselectivity.

Evaluation of SILP-Pd catalysts for Heck reactions in a microfluidics-based high throughput flow reactor

Heck reaction of aryl iodides and methyl acrylate was carried out in an X-Cube reactor in the presence of supported catalysts. Palladium was immobilised by different methods on silica with covalently grafted ionic liquid moieties. Activity and selectivity of the SILP-Pd (supported ionic liquid phase) catalysts were found to depend greatly on the conditions (such as solvent and additives) of immobilisation. By the proper choice of the methodology used during heterogenisation, a selective catalyst, showing stable performance for hours on stream, was obtained.

Chirality holds the key for potent inhibition of the botulinum neurotoxin serotype a protease

(Chemical Equetion Presentation) Botulinum neurotoxin serotype A (BoNT/A) is the most toxic protein known to man and also a bioterrorism agent. As defined by our previous research targeting the etiological agent responsible for BoNT/A intoxication, a protease, we now report on the asymmetric synthesis of four new BoNT/A inhibitors; the most potent of this series is roughly 2-fold more active than the best small molecule inhibitor currently known.

ATP-citrate lyase as a target for hypolipidemic intervention. Design and synthesis of 2-substituted butanedioic acids as novel, potent inhibitors of the enzyme

ATP-citrate lyase is the primary enzyme responsible for the synthesis of cytosolic acetyl-CoA in many tissues. Inhibitors of the enzyme represent a potentially novel class of hypolipidemic agent, which are anticipated to have combined hypocholesterolemic and hypotriglyceridemic properties. A series of 2-substituted butanedioic acids have been designed and synthesized as inhibitors of the enzyme. The best compounds, 58, 68, 71, 74 have reversible K(i)'s in the 1-3 μM range against the isolated rat enzyme. As representative of this compound class, 58, has been shown to exert its inhibitory action through a mainly competitive mechanism with respect to citrate and a noncompetitive one with respect to CoA. None of the inhibitors were able to inhibit cholesterol and/or fatty acid synthesis in HepG2 cells. This has been attributed to the adverse physicochemical properties of the molecules leading to a lack of cell penetration. Despite this, a lead structural class of compound has been identified with the potential for modification into potent, cell-penetrant, and efficacious inhibitors of ATP- citrate lyase.